Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

Affiliations

¹ V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia.
² Oncological Center No.1 of Moscow City Hospital Named After S.S. Yudin, Moscow, Russia.
³ A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center, Krasnoyarsk, Russia.
⁴ Republican Clinical Oncology Dispensary, Ufa, Russia.
⁵ Saint-Petersburg State University, Saint-Petersburg, Russia.
⁶ Clinical Hospital #1, Medsi Otradnoe, Moscow, Russia.
⁷ Department of Medical Oncology, SBHI Leningrad Regional Clinical Hospital, Saint-Petersburg, Russia.
⁸ N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
⁹ Sakhalin Regional Clinical Oncology Dispensary, Yuzhno-Sakhalinsk, Russia.
¹⁰ Birobidzhan Regional Cancer Center, Birobidzhan, Russia.
¹¹ Center for Immunotherapy and Targeted Therapy, Moscow, Russia.
¹² P.A. Herzen Moscow Oncological Research Institute, Moscow, Russia.
¹³ Sverdlovskiy Regional Oncological Dispensary, Ekaterinburg, Russia.
¹⁴ Tula Regional Oncology Dispensary, Tula, Russia.
¹⁵ Tyumen State Medical University, Tyumen, Russia.
¹⁶ Amur Regional Oncology Center, Blagoveshchensk, Russia.
¹⁷ Republican Dispensary of Tatarstan, Kazan, Russia.
¹⁸ Novosibirsk Regional Cancer Center, Novosibirsk, Russia.
¹⁹ Omsk Regional Cancer Center, Omsk, Russia.
²⁰ Tver Regional Cancer Center, Tver, Russia.
²¹ Khabarovsk Regional Cancer Center, Khabarovsk, Russia.
²² Bureau for Cancer Research - Moscow office, Moscow, Russia.

Ruslan Zukov et al. BJU Int. 2025.

. 2025 Aug 28.

doi: 10.1111/bju.16921. Online ahead of print.

¹ V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia.
² Oncological Center No.1 of Moscow City Hospital Named After S.S. Yudin, Moscow, Russia.
³ A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center, Krasnoyarsk, Russia.
⁴ Republican Clinical Oncology Dispensary, Ufa, Russia.
⁵ Saint-Petersburg State University, Saint-Petersburg, Russia.
⁶ Clinical Hospital #1, Medsi Otradnoe, Moscow, Russia.
⁷ Department of Medical Oncology, SBHI Leningrad Regional Clinical Hospital, Saint-Petersburg, Russia.
⁸ N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
⁹ Sakhalin Regional Clinical Oncology Dispensary, Yuzhno-Sakhalinsk, Russia.
¹⁰ Birobidzhan Regional Cancer Center, Birobidzhan, Russia.
¹¹ Center for Immunotherapy and Targeted Therapy, Moscow, Russia.
¹² P.A. Herzen Moscow Oncological Research Institute, Moscow, Russia.
¹³ Sverdlovskiy Regional Oncological Dispensary, Ekaterinburg, Russia.
¹⁴ Tula Regional Oncology Dispensary, Tula, Russia.
¹⁵ Tyumen State Medical University, Tyumen, Russia.
¹⁶ Amur Regional Oncology Center, Blagoveshchensk, Russia.
¹⁷ Republican Dispensary of Tatarstan, Kazan, Russia.
¹⁸ Novosibirsk Regional Cancer Center, Novosibirsk, Russia.
¹⁹ Omsk Regional Cancer Center, Omsk, Russia.
²⁰ Tver Regional Cancer Center, Tver, Russia.
²¹ Khabarovsk Regional Cancer Center, Khabarovsk, Russia.
²² Bureau for Cancer Research - Moscow office, Moscow, Russia.

No abstract available

References

1. Rouprêt M, Babjuk M, Compérat E et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015; 68: 868–879
1. Shatkovskaya O, Kaidarova D, Ongarbayev B, Sagi M, Tsimafeyeu I. Five‐year overall survival of patients with advanced bladder cancer in Kazakhstan: OSURK registry study. Am J Clin Exp Urol 2023; 11: 542–548
1. Favaretto RL, Shariat SF, Chade DC et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan‐Kettering Cancer Center. Eur Urol 2010; 58: 574–580
1. Necchi A, Raggi D, Gallina A et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following Neoadjuvant Pembrolizumab in muscle‐invasive bladder cancer. Eur Urol 2020; 77: 701–710
1. Bamias A, Tzannis K, Harshman LC et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the Urothelium (RISC). Ann Oncol 2018; 29: 361–369